“Rebating” is illegal in many industries, but not in the prescription medication marketplace apparently. It’s good to have friends in Congress.
(From The Hill)
Generally, a pharmaceutical company pays a rebate so a pharmacy benefit manager — the third-party administrators of prescription drug programs — will make its product the only one of its kind on the list approved for reimbursement or so that the co-pay for its product is less than the co-pay of competing products.
Trump administration officials have argued that if the federal anti-kickback law that protects such rebates were changed, it could help increase competition and make drugs more affordable.